MCA-205 Cells
1 104,00 CAD$*
Products are shipped frozen on dry ice in cryotubes. Each cryotube typically contains 3 × 106 cells for adherent lines or 5 × 106 cells for suspension lines (refer to the batch CoA for details).
Renseignements généraux
| Description | MCA-205 is a murine fibrosarcoma cell line derived from C57BL/6 mice. It was originally established through methylcholanthrene-induced tumorigenesis, a classic chemical carcinogenesis approach widely used to generate transplantable tumor models in syngeneic mice. MCA-205 serves as an immunocompetent tumor model, meaning it can be implanted into immunocompetent C57BL/6 mice without rejection, making it highly suitable for preclinical studies of cancer immunotherapy and tumor immunology. Biologically, MCA-205 tumors are classified as non-immunogenic or poorly immunogenic, a characteristic that reflects their low baseline antigenicity and reduced susceptibility to spontaneous immune-mediated rejection. This feature is particularly useful for evaluating the efficacy of checkpoint blockade therapies (such as anti-PD-1 or anti-CTLA-4) or tumor vaccines under conditions that mirror the immune-evasive nature of many human cancers. Despite their poor intrinsic immunogenicity, MCA-205 tumors can respond to immune modulation when combined with radiation therapy, oncolytic viruses, or TLR agonists, making them a versatile platform for combinatorial treatment testing. MCA-205 cells grow rapidly both in vitro and in vivo, forming aggressive fibrosarcomas when injected subcutaneously. These tumors have a high degree of vascularization and support reproducible tumor growth kinetics, allowing for consistent measurement of tumor burden and treatment response. Due to their murine origin and syngeneicity with C57BL/6 mice, MCA-205 cells are not appropriate for human-specific assays but are indispensable for exploring immune mechanisms in a fully functional host immune system. |
|---|---|
| Organisme | Mouse |
| Maladie | Mouse fibrosarcoma |
| Synonymes | MCA 205, MCA205 |
Caractéristiques
| Propriétés de croissance | Adherent |
|---|
Données réglementaires
| Référence | MCA-205 (Cytion catalog number 305730) |
|---|---|
| Niveau de biosécurité | 1 |
| NCBI_Numéro d'identification fiscale | 10090 |
| Cellosaurus - Numéro d'enregistrement | CVCL_VR90 |
Données biomoléculaires
| Profil mutationnel |
|---|
Manipulation
| Milieu de culture | RPMI 1640, w: 2.0 mM stable Glutamine, w: 2.0 g/L NaHCO3 (Cytion article number 820700a) |
|---|---|
| Suppléments | Supplement the medium with 10% FBS and 1% NEAA |
| Réactif de dissociation | Accutase |
| Milieu de congélation | As a cryopreservation medium, we use complete growth medium (including FBS) + 10% DMSO for adequate post-thaw viability, or CM-1 (Cytion catalog number 800100), which includes optimized osmoprotectants and metabolic stabilizers to enhance recovery and reduce cryo-induced stress. |
| Décongélation et culture des cellules |
|
| Atmosphère d'incubation | 37°C, 5% CO2, humidified atmosphere. |
| Conditions d'expédition | Cryopreserved cell lines are shipped on dry ice in validated, insulated packaging with sufficient refrigerant to maintain approximately −78 °C throughout transit. On receipt, inspect the container immediately and transfer vials without delay to appropriate storage. |
| Conditions d'entreposage | For long-term preservation, place vials in vapor-phase liquid nitrogen at about −150 to −196 °C. Storage at −80 °C is acceptable only as a short interim step before transfer to liquid nitrogen. |
Contrôle de la qualité et analyse moléculaire
| Stérilité | Mycoplasma contamination is excluded using both PCR-based assays and luminescence-based mycoplasma detection methods. To ensure there is no bacterial, fungal, or yeast contamination, cell cultures are subjected to daily visual inspections. |
|---|
Certificat d'analyse (CoA)
| Numéro de lot | Type de certificat | Date | Numéro de catalogue |
|---|---|---|---|
| 305730-161225 | Certificat d'analyse | 23. Apr. 2026 | 305730 |